About

Our Story

We launched Fulcrum Therapeutics with a bold vision: To change the course of genetically defined diseases by treating them at their root cause.

Our approach to drug discovery generates significant insights into disease biology and allows us to think creatively about the best way to modulate and balance gene expression. The result: FulcrumSeek, a patient-focused product engine designed to systematically identify and validate cellular drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases.

We take great pride in being purposeful patient partners who do this work, not just for patients, but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it. In addition, we are invested in our people and want to ensure they have the tools and training they need to succeed. This allows our playful spirit to come alive, making work more enjoyable for our entire Fulcrew.

Bryan Stuart

Bryan Stuart

President and Chief Executive Officer, Board Member
Bryan Stuart
Chief Operating Officer
Bryan Stuart was named president and chief executive officer of Fulcrum Therapeutics in March 2021. He joined Fulcrum as chief operating officer in 2018, bringing over 20 years of industry experience, predominantly in the rare disease space. He has played a leadership role in advancing numerous rare disease programs from the clinic to commercialization. Prior to joining Fulcrum, Bryan was president and CEO of Yarra Therapeutics, a subsidiary of Array BioPharma focused on genetically defined rare diseases. He also served as president and then CEO of Kastle Therapeutics, a biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases. Prior to Kastle, Bryan was chief business officer of Civitas Therapeutics, where he led the business development, capital raising, commercial and portfolio management functions including a planned IPO and eventual sale of the company to Acorda Therapeutics. He also led business development, corporate development and strategy at EKR Therapeutics (acquired by Chiesi) and Ovation Pharmaceuticals (acquired by Lundbeck A/S), where he played key roles in the successful sales of both companies. Bryan began his career as a healthcare investment banker at William Blair & Company. He has an MBA from the Kellogg School at Northwestern University and a bachelor’s degree from the University of Illinois.

Judith Dunn, Ph.D.

Judith Dunn, Ph.D.

President, Research & Development

Judith Dunn, Ph.D. joined Fulcrum in April 2021 as president, research & development. In her career she has held leadership roles in all phases of drug development from discovery through commercialization. Most recently, Judy served as entrepreneur in residence at Atlas Venture, where she led the formation of new companies positioned to address areas of unmet need in neuroscience. She is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. Previously, Judy served as vice president of clinical development at Roche in Basel, Switzerland and head of the Roche Innovation Center in NYC. While in New York, she participated in the establishment of the Empire Discovery Institute, a NY State effort to catalyze the progression of academic discovery research to clinical application. She has held positions in both the research and commercial divisions of Pfizer and led clinical programs in psychiatry at Sunovion (Sepracor). Judy received a postdoctoral fellowship in clinical research from Pfizer and a training fellowship in neuropharmacology from the Center for Brain Research at Strong Memorial Hospital. She earned her undergraduate degree in neuroscience at University of Rochester and her graduate degree in neurobiology at Wesleyan University.

Christopher Moxham, Ph.D.

Christopher Moxham, Ph.D.

Chief Scientific Officer

Chris Moxham, Ph.D. joined Fulcrum in January 2019 as senior vice president of Discovery Research before being promoted to chief scientific officer in January 2021. He has more than two decades of experience in drug discovery. Prior to joining Fulcrum, Chris worked at Eli Lilly and Company where he helped grow the organization’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art laboratory facility focused on preclinical and translational research. He has led teams that have delivered numerous small and large molecules into clinical development. Chris serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation. He earned his B.S. in biological sciences from Cornell University and his Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook before conducting postdoctoral training at SUNY Stony Brook.

Kim Hazen

Kim Hazen

Senior Vice President, Human Resources
Kim Hazen
Vice President, Human Resources
Kim Hazen joined Fulcrum in September 2017 with over 25 years of experience in human resources. Most recently, she was vice president of human resources at Warp Drive Bio, where she led efforts to build a drug discovery culture and core values to match with an emphasis on elite performance. Prior to joining Fulcrum and Warp Drive Bio, Kim served as the executive director of human resources at Aegerion Pharmaceuticals and as head of human resources at the Broad Institute of MIT and Harvard. Before joining the life sciences industry, she worked on the investment side of human resources at Pioneer Investments, Fidelity Investments, Liberty Mutual and Bank of America. Kim received a bachelor’s in psychology from SUNY Potsdam and her MBA from Boston University.

Pamela Strode

Pamela Strode

Senior Vice President, Regulatory Affairs and Quality Assurance
Pamela S. Strode
Senior Vice President, Regulatory Affairs and Quality Assurance
Pamela (Pam) Strode joined Fulcrum in September 2019. She comes to Fulcrum from Epizyme, where she served as senior vice president, regulatory affairs and quality assurance, and played a critical role in establishing the team’s regulatory affairs and quality assurance departments. At Epizyme, Pam directed multiple U.S. Fast Track and U.S./E.U. Orphan Drug Designations and also led the regulatory strategy and operations for several clinical trial applications and a New Drug Application (NDA). She brings more than 30 years of regulatory leadership for investigational and marketed products across multiple therapeutic areas, with increasing levels of responsibility at Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc. and Cerulean Pharma. Pam has a B.S. in microbiology from Cook College at Rutgers University and an M.S. in QA/RA from Temple University, where she also obtained a Drug Development Certificate.

Peter Thomson

Peter Thomson

Vice President, Finance and Accounting
Peter Thomson
Vice President, Finance and Accounting
Peter Thomson joined Fulcrum in 2018, bringing over 15 years of experience in the life sciences industry. Most recently, he was a consultant for three Third Rock Ventures portfolio companies, where he served as interim head of finance. Before that, he served as head of finance at BIND Therapeutics, where he oversaw all finance and accounting activities, developed the corporate valuation for the company and played an integral role in the company’s sale to Pfizer. Prior to BIND, he was senior director of finance at Ovascience and director of finance at Millennium: The Takeda Oncology Company. In addition, he held positions on the finance teams at Boston Scientific Corporation, Infomedics, Inc., and the Hewlett-Packard Company. Peter earned a bachelor’s from Brown University and an MBA from the University of Chicago Booth School of Business.
sdf

Nicole T. Gallagher

Nicole T. Gallagher

Director, Administration

Nicole T. Gallagher is Director of Administration and Executive Assistant to the CEO at Fulcrum Therapeutics, where she leads management of a range of operational areas including internal and external communications, collaboration with patient communities and vendors, planning and execution of needs related to the company board of directors and strategies to develop and promote corporate culture, cross-team collaboration and team building. Prior to joining Fulcrum, Nicole’s 20-year career has included lead roles in administration at companies including Abcam, Tapestry Networks, Aviva Life Insurance and Enterprise Rent-A-Car. In her previous roles she has executed strategies to strengthen client, customer and employee relationships, managed and executed corporate global events, and overseen the daily administration of office operations. In healthcare industry settings she has also spearheaded efforts to help team members connect directly with patients, noting, “To see and hear directly from patients tells us what we’re working towards and makes it more real.”

sdf

Curtis Oltmans, JD

Curtis Oltmans, JD

General Counsel

Curtis Oltmans, JD joined Fulcrum as General Counsel in November 2020 with over 25 years of experience in
corporate law including senior management positions in legal departments at several leading
pharmaceutical and biotechnology companies. He most recently served as Vice President, Head of
Litigation at DaVita Kidney Care, Inc. where he led a 30-person team and was responsible for all
litigation, workers’ compensation and employee safety matters. Prior to DaVita, Curtis was Executive
Vice President, General Counsel and Corporate Secretary at Array BioPharma Inc. where he oversaw all
legal, corporate governance, patent and compliance matters. He previously served as Corporate Vice
President and General Counsel for Novo Nordisk, Inc., North America where he was responsible for
strategic support in areas including market access, government affairs, communications and product
marketing. He has also served as Assistant General Counsel for Eli Lilly and Company after beginning his
legal career supporting clients in pharmaceutical and medical device litigation matters. Curtis received a
BA in political science from the University of Nebraska and his JD from the University of Nebraska
College of Law.

Christopher Morabito, MD

Christopher Morabito, MD

Chief Medical Officer

Chris Morabito, MD has extensive leadership experience at biotechnology and pharmaceutical companies and has advanced discovery and clinical programs including Phase 1, proof-of-concept and pivotal studies. Most recently, he served as chief medical officer at Cardurion Pharmaceuticals where he oversaw all drug development activities. Prior to Cardurion, he served in several roles at Takeda, including program leadership and head of pipeline strategy, most recently serving as senior vice president and head of research and development for plasma-derived protein therapies. He also led programs from early development stage through regulatory submission at Sanofi and he began his career in industry at Merck & Co, leading development of multiple cardiovascular assets. Chris was also chief of the division of neonatology at Lehigh Valley Hospital and Health Network. He trained initially as a neonatologist at the University of California, San Francisco. He earned his B.A. in biology from Franklin and Marshall College, and his M.D. from Penn State University College of Medicine.

Mani Sundararajan, Ph.D.

Mani Sundararajan, Ph.D.

Senior Vice President, Technical Operations

Mani Sundararajan, Ph.D., joined Fulcrum in July 2021 as senior vice president, technical operations. Most recently he worked at Seagen, where he led several technical operations functions including small molecules process development, CMC strategy and program management. He has also held leadership positions in drug development and technical operations at Takeda, Shire, AstraZeneca, Bristol-Myers Squibb and DuPont Pharmaceuticals. Mani has a B.Sc.(Tech.) in pharmaceuticals & fine chemicals technology from the Institute of Chemical Technology at University of Mumbai, India, an M.S. and Ph.D. in pharmaceutical sciences from Temple University, and an executive masters in technology management from University of Pennsylvania’s School of Engineering & Applied Science and Wharton.